vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and RADIANT LOGISTICS, INC (RLGT). Click either name above to swap in a different company.
RADIANT LOGISTICS, INC is the larger business by last-quarter revenue ($232.1M vs $196.9M, roughly 1.2× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -12.3%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $11.6M). Over the past eight quarters, RADIANT LOGISTICS, INC's revenue compounded faster (12.1% CAGR vs 8.5%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Radiant Logistics, Inc. is a leading third-party logistics provider offering end-to-end supply chain solutions, domestic and international freight forwarding, warehousing, and last-mile delivery services. It primarily serves North American markets, with key client segments including retail, manufacturing, e-commerce, and industrial sectors, helping businesses optimize logistics workflows and cut operational costs.
PCRX vs RLGT — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.9M | $232.1M |
| Net Profit | — | $5.3M |
| Gross Margin | 79.5% | — |
| Operating Margin | 1.2% | 3.2% |
| Net Margin | — | 2.3% |
| Revenue YoY | 5.1% | -12.3% |
| Net Profit YoY | — | -18.0% |
| EPS (diluted) | $0.05 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.9M | $232.1M | ||
| Q3 25 | $179.5M | $226.7M | ||
| Q2 25 | $181.1M | $220.6M | ||
| Q1 25 | $168.9M | $214.0M | ||
| Q4 24 | $187.3M | $264.5M | ||
| Q3 24 | $168.6M | $203.6M | ||
| Q2 24 | $178.0M | $206.0M | ||
| Q1 24 | $167.1M | $184.6M |
| Q4 25 | — | $5.3M | ||
| Q3 25 | $5.4M | $1.3M | ||
| Q2 25 | $-4.8M | $4.9M | ||
| Q1 25 | $4.8M | $2.5M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $-143.5M | $3.4M | ||
| Q2 24 | $18.9M | $4.8M | ||
| Q1 24 | $9.0M | $-703.0K |
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — | ||
| Q1 24 | 71.6% | — |
| Q4 25 | 1.2% | 3.2% | ||
| Q3 25 | 3.5% | 0.9% | ||
| Q2 25 | 4.7% | 2.4% | ||
| Q1 25 | 1.2% | 1.6% | ||
| Q4 24 | 13.2% | 3.3% | ||
| Q3 24 | -82.8% | 1.9% | ||
| Q2 24 | 15.9% | 2.4% | ||
| Q1 24 | 7.9% | -0.5% |
| Q4 25 | — | 2.3% | ||
| Q3 25 | 3.0% | 0.6% | ||
| Q2 25 | -2.7% | 2.2% | ||
| Q1 25 | 2.8% | 1.2% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | -85.1% | 1.7% | ||
| Q2 24 | 10.6% | 2.3% | ||
| Q1 24 | 5.4% | -0.4% |
| Q4 25 | $0.05 | $0.11 | ||
| Q3 25 | $0.12 | $0.03 | ||
| Q2 25 | $-0.11 | $0.10 | ||
| Q1 25 | $0.10 | $0.05 | ||
| Q4 24 | $0.38 | $0.13 | ||
| Q3 24 | $-3.11 | $0.07 | ||
| Q2 24 | $0.39 | $0.11 | ||
| Q1 24 | $0.19 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.4M | $31.9M |
| Total DebtLower is stronger | $372.2M | — |
| Stockholders' EquityBook value | $693.1M | $229.8M |
| Total Assets | $1.3B | $439.4M |
| Debt / EquityLower = less leverage | 0.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.4M | $31.9M | ||
| Q3 25 | $246.3M | $28.1M | ||
| Q2 25 | $445.9M | $22.9M | ||
| Q1 25 | $493.6M | $19.0M | ||
| Q4 24 | $484.6M | $19.9M | ||
| Q3 24 | $453.8M | $10.4M | ||
| Q2 24 | $404.2M | $24.9M | ||
| Q1 24 | $325.9M | $31.2M |
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | $229.8M | ||
| Q3 25 | $727.2M | $225.7M | ||
| Q2 25 | $757.8M | $226.0M | ||
| Q1 25 | $798.5M | $218.2M | ||
| Q4 24 | $778.3M | $214.4M | ||
| Q3 24 | $749.6M | $212.4M | ||
| Q2 24 | $879.3M | $209.4M | ||
| Q1 24 | $892.2M | $206.0M |
| Q4 25 | $1.3B | $439.4M | ||
| Q3 25 | $1.3B | $445.3M | ||
| Q2 25 | $1.5B | $426.8M | ||
| Q1 25 | $1.6B | $414.5M | ||
| Q4 24 | $1.6B | $386.8M | ||
| Q3 24 | $1.5B | $375.3M | ||
| Q2 24 | $1.6B | $371.2M | ||
| Q1 24 | $1.6B | $364.0M |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.7M | $12.4M |
| Free Cash FlowOCF − Capex | $43.5M | $11.6M |
| FCF MarginFCF / Revenue | 22.1% | 5.0% |
| Capex IntensityCapex / Revenue | 0.1% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 2.33× |
| TTM Free Cash FlowTrailing 4 quarters | $136.7M | $8.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.7M | $12.4M | ||
| Q3 25 | $60.8M | $2.5M | ||
| Q2 25 | $12.0M | $3.1M | ||
| Q1 25 | $35.5M | $-5.7M | ||
| Q4 24 | $33.1M | $15.7M | ||
| Q3 24 | $53.9M | $205.0K | ||
| Q2 24 | $53.2M | $1.3M | ||
| Q1 24 | $49.1M | $3.9M |
| Q4 25 | $43.5M | $11.6M | ||
| Q3 25 | $57.0M | $977.0K | ||
| Q2 25 | $9.3M | $2.2M | ||
| Q1 25 | $26.9M | $-6.4M | ||
| Q4 24 | $31.0M | $14.1M | ||
| Q3 24 | $49.8M | $-1.9M | ||
| Q2 24 | $51.6M | $-185.0K | ||
| Q1 24 | $46.3M | $1.8M |
| Q4 25 | 22.1% | 5.0% | ||
| Q3 25 | 31.7% | 0.4% | ||
| Q2 25 | 5.1% | 1.0% | ||
| Q1 25 | 15.9% | -3.0% | ||
| Q4 24 | 16.6% | 5.3% | ||
| Q3 24 | 29.6% | -0.9% | ||
| Q2 24 | 29.0% | -0.1% | ||
| Q1 24 | 27.7% | 1.0% |
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 2.2% | 0.7% | ||
| Q2 25 | 1.5% | 0.4% | ||
| Q1 25 | 5.1% | 0.3% | ||
| Q4 24 | 1.1% | 0.6% | ||
| Q3 24 | 2.4% | 1.0% | ||
| Q2 24 | 0.9% | 0.7% | ||
| Q1 24 | 1.7% | 1.2% |
| Q4 25 | — | 2.33× | ||
| Q3 25 | 11.20× | 1.90× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | 7.37× | -2.26× | ||
| Q4 24 | — | 2.43× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | 2.82× | 0.26× | ||
| Q1 24 | 5.47× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
RLGT
| Transferred Over Time | $201.2M | 87% |
| Other | $25.0M | 11% |
| Value Added Services | $4.2M | 2% |
| Transferred At Point In Time | $1.8M | 1% |
